VEGFA and retinopathy of prematurity: Vascular endothelial growth factor (VEGF) inhibitors have proven to be efficient pharmacotherapy in ROP, however there are serious concerns with systemic toxicity of this drugs due to non-selective VEGF blockade, as well as the risk of ROP re-activation after cessation of use2.